
Lundbeck is to buy Alder Biopharmaceuticals for $2 billion enhancing its leading portfolio of brain disease therapies through the acquisition …
Amphista doses first patient in AML trial of protein degrader
Jennings becomes President of Beckman Coulter Diagnostics
Boyds expands Regulatory Affairs team to support growing demand

